Tag Archives: navigator

New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo

ACCORD/INVEST: do not aim for normal blood pressure in diabetes patients with CAD The results of two trials comparing intensive versus more conventional blood pressure lowering in patients with diabetes at high cardiovascular risk have suggested that intensive treatment is not necessary and may be harmful in this population. In the ACCORD BP (Action to Control Cardiovascular Risk in Diabetes – Blood Pressure) trial, while intensive blood pressure treatment did reduce the risk of stroke, it failed to reduce the overall risk of cardiovascular events in patients and was associated with an increase in adverse events due to antihypertensive ther